JP7153938B2 - 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 - Google Patents

認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 Download PDF

Info

Publication number
JP7153938B2
JP7153938B2 JP2019554038A JP2019554038A JP7153938B2 JP 7153938 B2 JP7153938 B2 JP 7153938B2 JP 2019554038 A JP2019554038 A JP 2019554038A JP 2019554038 A JP2019554038 A JP 2019554038A JP 7153938 B2 JP7153938 B2 JP 7153938B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
membered heteroaryl
aliphatic
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512389A5 (https=
JP2020512389A (ja
Inventor
ブリュー メコネン，
ジョン エー． ブテーラ，
ジアンシン フアン，
Original Assignee
エージンバイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エージンバイオ， インコーポレイテッド filed Critical エージンバイオ， インコーポレイテッド
Publication of JP2020512389A publication Critical patent/JP2020512389A/ja
Publication of JP2020512389A5 publication Critical patent/JP2020512389A5/ja
Application granted granted Critical
Publication of JP7153938B2 publication Critical patent/JP7153938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019554038A 2016-12-19 2017-12-20 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 Active JP7153938B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436272P 2016-12-19 2016-12-19
US62/436,272 2016-12-19
PCT/IB2017/001763 WO2018130869A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
PCT/IB2017/001762 WO2018130868A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IBPCT/IB2017/001763 2017-12-20

Publications (3)

Publication Number Publication Date
JP2020512389A JP2020512389A (ja) 2020-04-23
JP2020512389A5 JP2020512389A5 (https=) 2021-02-04
JP7153938B2 true JP7153938B2 (ja) 2022-10-17

Family

ID=62557208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554038A Active JP7153938B2 (ja) 2016-12-19 2017-12-20 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Country Status (10)

Country Link
US (2) US20180170941A1 (https=)
EP (1) EP3555100B1 (https=)
JP (1) JP7153938B2 (https=)
CN (2) CN116640143A (https=)
AU (1) AU2017393082B2 (https=)
CA (1) CA3047684A1 (https=)
EA (1) EA201991497A1 (https=)
IL (1) IL267451B2 (https=)
MX (1) MX388726B (https=)
WO (2) WO2018130869A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528427A (ja) * 2018-06-19 2021-10-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
IL294031A (en) * 2019-12-19 2022-08-01 Agenebio Inc History of benzodiazepines, preparations and methods for the treatment of cognitive impairment
CA3189302A1 (en) * 2020-07-10 2022-01-13 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
JP2023534190A (ja) * 2020-07-10 2023-08-08 エージンバイオ， インコーポレイテッド ＧＡＢＡＡα５アゴニストの多形および認知障害の処置において使用する方法
CN113413532B (zh) * 2021-07-01 2022-03-01 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517070A (ja) 2000-11-16 2004-06-10 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇａｂａａ受容体モデュレーターとしてのベンゾジアゼピン誘導体
JP2008515941A (ja) 2004-10-12 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー 置換ベンゾジアゼピン誘導体
JP2008517011A (ja) 2004-10-20 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー イミダゾベンゾジゼピン誘導体
JP2008517010A (ja) 2004-10-20 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー ハロゲン置換ベンゾジアゼピン誘導体
JP2008523125A (ja) 2004-12-14 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー Ｇａｂａレセプタ調節物質としての四環系イミダゾ−ベンゾジアゼピン類
JP2013542266A (ja) 2010-11-15 2013-11-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法
JP2013544808A (ja) 2010-11-05 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための活性医薬化合物の使用
JP2015509935A (ja) 2012-02-14 2015-04-02 中国科学院上海生命科学研究院 痛みを治療・緩和する物質
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
WO1992020682A1 (en) 1991-05-24 1992-11-26 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (https=) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
JP4099224B2 (ja) 1994-03-02 2008-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン 舌下又はバッカル医薬組成物
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
AU1041599A (en) 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
WO2000027849A2 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
WO2000051985A1 (en) 1999-03-03 2000-09-08 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2002069948A1 (en) 2001-03-01 2002-09-12 Pfizer Products Inc. Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1471909A4 (en) 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
CA2495285A1 (en) 2002-08-13 2004-02-19 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
KR100777904B1 (ko) 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
US20040191803A1 (en) 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
CN1870984A (zh) 2003-10-22 2006-11-29 莫茨药物股份两合公司 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
US20060079582A1 (en) 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1888594A2 (en) 2005-05-16 2008-02-20 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
KR101009860B1 (ko) 2005-10-11 2011-01-19 에프. 호프만-라 로슈 아게 이미다조 벤조다이아제핀 유도체
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010036553A1 (en) 2008-09-24 2010-04-01 E. I. Du Pont De Nemours And Company Fungicidal pyridazines
BRPI0920515B1 (pt) 2008-09-25 2018-03-20 Vive Nano, Inc. Composição compreendendo nanopartícula de polímero e composto ativo agrícola
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
US8853219B2 (en) 2010-01-11 2014-10-07 Neurosolis, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012161133A1 (ja) 2011-05-20 2012-11-29 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
AU2013312240A1 (en) 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
CN108567786A (zh) 2017-03-10 2018-09-25 陈洪国 一种治疗溃疡性结肠炎的药物组合物
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL294031A (en) * 2019-12-19 2022-08-01 Agenebio Inc History of benzodiazepines, preparations and methods for the treatment of cognitive impairment

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517070A (ja) 2000-11-16 2004-06-10 エフ．ホフマン−ラ　ロシュ　アーゲー Ｇａｂａａ受容体モデュレーターとしてのベンゾジアゼピン誘導体
JP2008515941A (ja) 2004-10-12 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー 置換ベンゾジアゼピン誘導体
JP2008517011A (ja) 2004-10-20 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー イミダゾベンゾジゼピン誘導体
JP2008517010A (ja) 2004-10-20 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー ハロゲン置換ベンゾジアゼピン誘導体
JP2008523125A (ja) 2004-12-14 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー Ｇａｂａレセプタ調節物質としての四環系イミダゾ−ベンゾジアゼピン類
JP2013544808A (ja) 2010-11-05 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための活性医薬化合物の使用
JP2013542266A (ja) 2010-11-15 2013-11-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法
JP2015509935A (ja) 2012-02-14 2015-04-02 中国科学院上海生命科学研究院 痛みを治療・緩和する物質
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ACHERMANN, Guido，Bioorg.Med.Chem.Lett.，2009年，19，5746-5752
Alajarin, Mateo; Cabrera, Jose; Pastor, Aurelia; Villalgordo, Jose M.，A new modular and flexible approach to [1,2,3]triazolo[1,5-a][1,4]benzodiazepines，Tetrahedron Letters，2007年，48(20)，3495-3499
Buettelmann, Bernd et al.，Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA α5 i，Bioorganic & Medicinal Chemistry Letters，2009年，19(20)，5958-5961
Di Braccio, Mario et al.，1,5-Benzodiazepines XIV. Synthesis of new substituted 9H-bis-[1,2,4]triazolo[4,3-a:3',4'-d] [1,5]ben，Il Farmaco，2005年，60(2)，113-125
Donald, James R. et al.，Application of a Sequential Multicomponent Assembly Process/Huisgen Cycloaddition Strategy to the Pr，ACS Combinatorial Science，2012年，14(2)，135-143
El Youssoufi, Jawad et al.，Glycosylated benzocycloheptadipyrazoles: a new class of water-soluble heterocyclic compounds，Bulletin de la Societe Chimique de France，1997年，134(6)，571-581
Essassi, E. M. et al.，Research on 1,5-benzodiazepines. Synthesis of [4,3-a; 3,4-d]triazolo-1,5-benzodiazepines，Bulletin des Societes Chimiques Belges，1991年，100(3)，277-286
GERECKE, Max，HETEROCYCLES，1994年，39(2)，693-721
Gharaghani, Sajjad et al.，A structure-based QSAR and docking study on imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4,]benzodiazepin，Chemical Biology & Drug Design，2011年，78(4)，612-621
HUSSAIN, Mohd. Kamil，Organic Letters，2014年，16，560-563
JONAS, Oliver，Journal of Biomedical Nanotechnology，2016年，12，1297-1302
Knust, Henner et al.，The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective，Bioorganic & Medicinal Chemistry Letters，2009年，19(20)，5940-5944
Korakas, Demetrios et al.，Synthesis of novel pyrrolo[2,1-d][1,2,5]benzotriazepine, pyrrolo[2,1-e][1,3,6]benzotriazocine and py，Tetrahedron，1996年，52(32)，10751-10760
Nguyen, Huy H. et al.，Facile One-Pot Assembly of Imidazotriazolobenzodiazepines via Indium(III)-Catalyzed Multicomponent R，Organic Letters，2013年，15(17)，4492-4495
Ried, Walter; Aboul-Fetouh, Saleh，Syntheses of new 1,3-diazepines，Chemiker-Zeitung，1987年，111(5)，179-180
SENGUPTA, Soma，Acta Neuropathologica，2013年11月07日，DOI 10.1007/s00401-013-1205-7
Xiang, Jin-Bao; Zhu, Tong; Dang, Qun; Bai, Xu，Stereochemistry as a Tool in Deciphering the Processes of a Tandem Iminium Cyclization and Smiles Re，Journal of Organic Chemistry，2010年，75(23)，8147-8154

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528427A (ja) * 2018-06-19 2021-10-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Also Published As

Publication number Publication date
EA201991497A1 (ru) 2020-01-20
US20180170941A1 (en) 2018-06-21
CA3047684A1 (en) 2018-07-19
MX388726B (es) 2025-03-20
CN110382501A (zh) 2019-10-25
CN116640143A (zh) 2023-08-25
AU2017393082B2 (en) 2022-04-21
AU2017393082A1 (en) 2019-07-25
MX2019007338A (es) 2019-09-19
WO2018130869A1 (en) 2018-07-19
IL267451B1 (en) 2023-06-01
WO2018130868A1 (en) 2018-07-19
US12528819B2 (en) 2026-01-20
EP3555100B1 (en) 2023-05-10
IL267451A (en) 2019-08-29
EP3555100A1 (en) 2019-10-23
JP2020512389A (ja) 2020-04-23
IL267451B2 (en) 2023-10-01
EP3555100A4 (en) 2020-06-10
WO2018130868A8 (en) 2019-08-08
US20230134844A1 (en) 2023-05-04
NZ755287A (en) 2025-06-27

Similar Documents

Publication Publication Date Title
JP7153938B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
CN112409363B (zh) 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
US12024525B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40077472A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220927

R150 Certificate of patent or registration of utility model

Ref document number: 7153938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150